{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T16:27:46Z","timestamp":1789921666991,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T00:00:00Z","timestamp":1606435200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Swedish Research Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100002794","name":"Cancerfonden","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002794","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Stockholm Cancer Society"},{"name":"Swedish Cancer and Allergy Foundation"},{"DOI":"10.13039\/501100003514","name":"Stockholm City Council","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003514","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Gynecol Obstet"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Three human papillomavirus (HPV) vaccines are available against up to nine HPV types. In Sweden, from 2012, Gardasil was offered to 10\u221212\u00a0year old girls through the school-based vaccination program, and as catchup vaccination for women up to 26\u00a0years. To obtain a baseline, and follow HPV vaccination effects, during 2008\u22122018, cervical and oral HPV prevalence were followed at a youth clinic in Stockholm, and in 2013 for comparison oral HPV prevalence was examined in high-school youth in a middle-sized county in Sweden. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this review, we discuss all our data with cervical and oral mouthwash samples that were collected and tested for 24\u221227 HPV types by a bead-based multiplex assay from 2008. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Compared with 2008\u22122011, with\u2009~\u200935% HPV16 and\u2009&gt;\u200960% high risk (HR) HPV cervical prevalence at the youth clinic, a decrease of vaccine HPV types was observed between 2013 and 2018, with e.g., HPV16 falling to 5% in catchup vaccinated women\u00a0and 15\u221218% in nonvaccinated women. Most common cervical HR-HPV types were HPV39, 51, 52, 56, and 59 together accounting for\u2009~\u200910% of cervical cancer, and where only HPV52 is included in Gardasil-9. At baseline 2009\u22122011, oral HPV prevalence was\u2009~\u200910% in unvaccinated youth at the youth clinic, but after 2013 it dropped to\u2009&lt;\u20092% at the youth clinic and high schools.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>To conclude, Gardasil HPV types have decreased, but it is still important to follow remaining HR-HPV types and cancer development, since there is an ongoing increase in the incidence of HPV-associated tonsillar and base of tongue cancer, and cervical cancer in Sweden.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00404-020-05879-7","type":"journal-article","created":{"date-parts":[[2020,11,27]],"date-time":"2020-11-27T18:03:11Z","timestamp":1606500191000},"page":"329-335","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Human papilloma virus (HPV) prevalence upon HPV vaccination in Swedish youth: a review based on our findings 2008\u20132018, and perspectives on cancer prevention"],"prefix":"10.1007","volume":"303","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7649-9571","authenticated-orcid":false,"given":"Juan","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"\u00c4hrlund-Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"N\u00e4sman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Dalianis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,27]]},"reference":[{"key":"5879_CR1","first-page":"127","volume":"88","author":"D DiMaio","year":"2015","unstructured":"DiMaio D (2015) Nuns, warts, viruses and cancer. Yale J Biol Med 88:127\u2013129","journal-title":"Yale J Biol Med"},{"key":"5879_CR2","doi-asserted-by":"publisher","first-page":"3812","DOI":"10.1073\/pnas.80.12.3812","volume":"80","author":"M Durst","year":"1983","unstructured":"Durst M, Gissmann L, Ikenberg H, zur Hausen H (1983) A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proc Natl Acad Sci USA 80:3812\u20133815","journal-title":"Proc Natl Acad Sci USA"},{"key":"5879_CR3","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/j.1460-2075.1984.tb01944.x","volume":"3","author":"M Boshart","year":"1984","unstructured":"Boshart M, Gissmann L, Ikenberg H, Kleinheinz A, Scheurlen W, zur Hausen H (1984) A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. Embo J. 3:1151\u20131157","journal-title":"Embo J."},{"key":"5879_CR4","first-page":"251","volume":"119","author":"N Munoz","year":"1992","unstructured":"Munoz N, Bosch FX (1992) HPV and cervical neoplasia: review of case-control and cohort studies. IARC Sci Publ 119:251\u2013261","journal-title":"IARC Sci Publ"},{"key":"5879_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2013.11.002","volume":"26","author":"M Tommasino","year":"2014","unstructured":"Tommasino M (2014) The human papillomavirus family and its role in carcinogenesis. Semin Cancer Biol 26:13\u201321. https:\/\/doi.org\/10.1016\/j.semcancer.2013.11.002 (Epub 2013 Dec 4)","journal-title":"Semin Cancer Biol"},{"key":"5879_CR6","volume-title":"IARC Monographs on the evaluation of Carcinogenic Risks to Humans","author":"IARC","year":"1995","unstructured":"IARC (1995) IARC Monographs on the evaluation of Carcinogenic Risks to Humans, vol 64. Human Papillomaviruses, Lyon"},{"key":"5879_CR7","doi-asserted-by":"crossref","unstructured":"Barra F. Maggiore URL, Bogani Get al. New prophylactic human papillomavirus (HPV) vaccines against cervical cancer. J Obstr Gynaecol 2019:39","DOI":"10.1080\/01443615.2018.1493441"},{"key":"5879_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1093\/jnci\/92.9.709","volume":"92","author":"ML Gillison","year":"2000","unstructured":"Gillison ML, Koch WM, Capone RB et al (2000) Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 92:709\u2013720","journal-title":"J Natl Cancer Inst"},{"key":"5879_CR9","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/1097-0215(20000520)89:3<300::AID-IJC14>3.0.CO;2-G","volume":"89","author":"H Mellin","year":"2000","unstructured":"Mellin H, Friesland S, Lewensohn R et al (2000) Human papillomavirus (HPV) DNA in tonsillar cancer: clinical correlates, risk of relapse, and survival. Int J Cancer 89:300\u2013304","journal-title":"Int J Cancer"},{"key":"5879_CR10","unstructured":"WHO. IARC Monographs on the Evaluation of carcinogenic risk to humans. Lyon, France: International Agency for Research on Cancer; 2007."},{"key":"5879_CR11","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.3201\/eid1611.100452","volume":"16","author":"T Ramqvist","year":"2010","unstructured":"Ramqvist T, Dalianis T (2010) Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 16:1671\u20131677","journal-title":"Emerg Infect Dis"},{"key":"5879_CR12","unstructured":"https:\/\/www.socialstyrelsen.se"},{"key":"5879_CR13","doi-asserted-by":"publisher","first-page":"3239","DOI":"10.1016\/j.vaccine.2018.04.073","volume":"36","author":"S V\u00e4nsk\u00e4","year":"2018","unstructured":"V\u00e4nsk\u00e4 S, S\u00f6derlund-Strand A, Uhnoo I et al (2018) Estimating effectiveness of HPV vaccination against HPV infection from post- vaccination data in the absence of baseline data. Vaccine 36:3239\u20133246","journal-title":"Vaccine"},{"key":"5879_CR14","doi-asserted-by":"publisher","first-page":"115","DOI":"10.3109\/00365548.2010.526957","volume":"43","author":"T Ramqvist","year":"2011","unstructured":"Ramqvist T, Du J, Lund\u00e9n M, Ahrlund-Richter S, Ferreira J, Marions L, Spar\u00e9n P et al (2011) Pre-vaccination prevalence of human papillomavirus types in the genital tract of 15\u201323-year-old women attending a youth health clinic in Stockholm. Sweden Scand J Infect Dis 43:115\u2013121","journal-title":"Sweden Scand J Infect Dis"},{"key":"5879_CR15","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.3201\/eid1809.111731","volume":"18","author":"J Du","year":"2012","unstructured":"Du J, Nordfors C, Ahrlund-Richter A et al (2012) Prevalence of oral human papillomavirus infection among youth. Sweden Emerg Infect Dis 18:1468\u20131471","journal-title":"Sweden Emerg Infect Dis"},{"key":"5879_CR16","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.3109\/0284186X.2011.584556","volume":"50","author":"J Du","year":"2011","unstructured":"Du J, N\u00e4sman A, Carlson JW et al (2011) Prevalence of human papillomavirus (HPV) types in cervical cancer 2003\u20132008 in Stockholm, Sweden, before public HPV vaccination. Acta Oncol 50:1215\u20131219","journal-title":"Acta Oncol"},{"key":"5879_CR17","doi-asserted-by":"publisher","first-page":"878","DOI":"10.3109\/00365548.2013.821626","volume":"45","author":"C Nordfors","year":"2013","unstructured":"Nordfors C, Gr\u00fcn N, Haeggblom L, Tertipis N et al (2013) Oral human papillomavirus prevalence in high school students of one municipality in Sweden. Scand J Infect Dis 45:878\u2013881","journal-title":"Scand J Infect Dis"},{"issue":"1","key":"5879_CR18","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3109\/00365548.2014.964764","volume":"47","author":"N Gr\u00fcn","year":"2015","unstructured":"Gr\u00fcn N, \u00c4hrlund-Richter A, Franz\u00e9n J, Mirzaie L, Marions L, Ramqvist T, Dalianis T (2015) Oral human papillomavirus (HPV) prevalence in youth and cervical HPV prevalence in women attending a youth clinic in Sweden, a follow up-study 2013\u20132014 after gradual introduction of public HPV vaccination. Infect Dis (Lond) 47(1):57\u201361","journal-title":"Infect Dis (Lond)"},{"key":"5879_CR19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.3109\/23744235.2015.1094573","volume":"48","author":"N Gr\u00fcn","year":"2016","unstructured":"Gr\u00fcn N, \u00c4hrlund-Richter A, Franz\u00e9n J et al (2016) Follow-up on oral and cervical human papillomavirus prevalence 2013\u20132015 in youth at a youth clinic in Stockholm, Sweden. Infect Dis (Lond) 48:169\u2013170","journal-title":"Infect Dis (Lond)"},{"key":"5879_CR20","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3389\/fcimb.2019.00059","volume":"9","author":"A \u00c4hrlund-Richter","year":"2019","unstructured":"\u00c4hrlund-Richter A, Cheng L, Hu YOO, Svensson M, Pennhag AAL, Ursu RG et al (2019) Changes in cervical human papillomavirus (HPV) prevalence at a youth clinic in Stockholm, Sweden, a decade after the introduction of the HPV vaccine. Front Cell Infect Microbiol 9:59","journal-title":"Front Cell Infect Microbiol"},{"key":"5879_CR21","first-page":"209","volume":"7","author":"MM Manos","year":"1989","unstructured":"Manos MM, Ting Y, Wright DK et al (1989) Use of polymerase chain reaction amplification for the detection of genital human papillomaviruses. Cancer Cells 7:209\u2013214","journal-title":"Cancer Cells"},{"key":"5879_CR22","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/S0140-6736(05)67069-9","volume":"366","author":"GM Clifford","year":"2005","unstructured":"Clifford GM, Gallus S, Herrero R et al (2005) Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. Lancet 366:991\u2013998","journal-title":"Lancet"},{"key":"5879_CR23","doi-asserted-by":"crossref","unstructured":"Drolet M, B\u00e9nard \u00c9, P\u00e9rez N, Brisson M; HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394:497\u2013509.","DOI":"10.1016\/S0140-6736(19)30298-3"},{"key":"5879_CR24","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1080\/23744235.2017.1300319","volume":"49","author":"N Gr\u00fcn","year":"2017","unstructured":"Gr\u00fcn N, Mbuya W, Ternhag A et al (2017) Human papillomavirus prevalence in mouthwashes of patients undergoing tonsillectomy shows dominance of HPV69, without the corresponding finding in the tonsils. Infect Dis (Lond) 49:588\u2013593","journal-title":"Infect Dis (Lond)"},{"key":"5879_CR25","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.anndiagpath.2018.10.008","volume":"38","author":"BJ Holmwa","year":"2019","unstructured":"Holmwa BJ, Wenig BM (2019) Virus-associated carcinomas of the head & neck: Update from the 2017 WHO classification. Ann Diagn Pathol. 38:29\u201342","journal-title":"Ann Diagn Pathol."},{"key":"5879_CR26","doi-asserted-by":"crossref","unstructured":"M\u00e9lanie D, \u00c9lodie B, Norma P, Marc B, the HPV Vaccination Impact Study Group. Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis. Lancet. 2019;394: 497\u2013509.","DOI":"10.1016\/S0140-6736(19)30298-3"},{"key":"5879_CR27","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.21873\/anticanres.14107","volume":"40","author":"S Malerova","year":"2020","unstructured":"Malerova S, Hejtmankova A, Hamsikova E, Salakova M, Smahelova J, Klozar J, Tachezy R (2020) Prevalence and risk factors for oral HPV in healthy population, in Central Europe. Anticancer Res 40:1597\u20131604","journal-title":"Anticancer Res"},{"key":"5879_CR28","doi-asserted-by":"crossref","unstructured":"Herrero R, Quint W, Hildesheim A, Gonzalez P, Struijk L, Katki HA, Porras C, Schiffman M, Rodriguez AC, Solomon D, Jimenez S, Schiller JT, Lowy DR, van Doorn LJ, Wacholder S, Kreimer AR; CVT Vaccine Group.\u00a0Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica.\u00a02013;8(7):e68329.","DOI":"10.1371\/journal.pone.0068329"},{"key":"5879_CR29","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.oraloncology.2014.02.012","volume":"50","author":"C Nordfors","year":"2014","unstructured":"Nordfors C, Vlastos A, Du J et al (2014) Human papillomavirus prevalence is high in oral samples of patients with tonsillar and base of tongue cancer. Oral Oncol 50:491\u2013497","journal-title":"Oral Oncol"},{"key":"5879_CR30","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/cncr.31256","volume":"124","author":"AR Kreimer","year":"2018","unstructured":"Kreimer AR, Shiels MS, Fakhry C et al (2018) Screening for human papillomavirus-driven oropharyngeal cancer: considerations for feasibility and strategies for research. Cancer 124:1859\u20131866","journal-title":"Cancer"},{"key":"5879_CR31","doi-asserted-by":"publisher","first-page":"6221","DOI":"10.1002\/cam4.2450","volume":"8","author":"L Haeggblom","year":"2019","unstructured":"Haeggblom L, \u00c4hrlund-Richter A, Mirzaie L et al (2019) Differences in gene expression between high-grade dysplasia and invasive HPV+ and HPV- tonsillar and base of tongue cancer. Cancer Med 8:6221\u20136232","journal-title":"Cancer Med"},{"issue":"1","key":"5879_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41522-020-00146-8","volume":"6","author":"LQ Cheng","year":"2020","unstructured":"Cheng LQ, Norenhag J, Hu YOO et al (2020) Vaginal microbiota and human papillomavirus infection among young Swedish women. NPJ Biofilms and Microbiomes 6(1):1\u201310","journal-title":"NPJ Biofilms and Microbiomes"},{"key":"5879_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1111\/1471-0528.15854","volume":"127","author":"J Norenhag","year":"2020","unstructured":"Norenhag J, Du J, Olovsson M, Verstraelen H et al (2020) The vaginal microbiota, human papillomavirus and cervical dysplasia: a systematic review and network meta-analysis. BJOG 127:171\u2013180","journal-title":"BJOG"},{"key":"5879_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajog.2018.12.011","volume":"221","author":"N Brusselaers","year":"2019","unstructured":"Brusselaers N, Shrestha S, van de Wijgert J, Verstraelen H (2019) Vaginal dyspoiosis and the risk of human papillomavirus and cervical cancer: systematic review and meta-analysis. Am J Obstdg Gynecol 221:9\u201318","journal-title":"Am J Obstdg Gynecol"},{"key":"5879_CR35","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1111\/joim.13010","volume":"287","author":"A N\u00e4sman","year":"2020","unstructured":"N\u00e4sman A, Du J, Dalianis T (2020) A global epidemic increase of an HPV-induced tonsil and tongue base cancer\u2014potential benefit from a pan-gender use of HPV vaccine. J Intern Med 287:134\u2013152","journal-title":"J Intern Med"}],"container-title":["Archives of Gynecology and Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05879-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00404-020-05879-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00404-020-05879-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T11:50:00Z","timestamp":1612353000000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00404-020-05879-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,27]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["5879"],"URL":"https:\/\/doi.org\/10.1007\/s00404-020-05879-7","relation":{},"ISSN":["0932-0067","1432-0711"],"issn-type":[{"value":"0932-0067","type":"print"},{"value":"1432-0711","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,27]]},"assertion":[{"value":"28 September 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}